loading
Elicio Therapeutics Inc stock is traded at $8.05, with a volume of 288.71K. It is up +1.13% in the last 24 hours and up +46.36% over the past month. Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
See More
Previous Close:
$7.96
Open:
$8.05
24h Volume:
288.71K
Relative Volume:
6.87
Market Cap:
$128.30M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.3146
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
+5.92%
1M Performance:
+46.36%
6M Performance:
+64.96%
1Y Performance:
+21.60%
1-Day Range:
Value
$7.865
$8.22
1-Week Range:
Value
$7.62
$8.22
52-Week Range:
Value
$3.3419
$9.99

Elicio Therapeutics Inc Stock (ELTX) Company Profile

Name
Name
Elicio Therapeutics Inc
Name
Phone
(857) 209-0050
Name
Address
451 D STREET, 5TH FLOOR, BOSTON
Name
Employee
26
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ELTX's Discussions on Twitter

Compare ELTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ELTX
Elicio Therapeutics Inc
8.05 128.30M 0 -33.82M -66.04M -25.59
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
440.87 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
509.72 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
309.70 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.15 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
247.08 28.51B 3.81B -644.79M -669.77M -6.24

Elicio Therapeutics Inc Stock (ELTX) Latest News

pulisher
Jun 18, 2025

Elicio Therapeutics Secures Strategic Financing As Pivotal Cancer Trial Data Approaches - Barchart.com

Jun 18, 2025
pulisher
Jun 17, 2025

Elicio Therapeutics to Host Virtual KOL Event on June 25, - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer - GlobeNewswire Inc.

Jun 17, 2025
pulisher
Jun 04, 2025

Elicio secures $10 million to extend cash runway By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Elicio Therapeutics Secures $10 Million in Financing - citybiz

Jun 04, 2025
pulisher
Jun 04, 2025

Elicio Therapeutics Gets $10 Million Note Financing - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Elicio secures $10 million to extend cash runway - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Elicio Therapeutics Secures $10M Financing for Operations - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Elicio Therapeutics (ELTX) Secures $10M Financing to Extend Operations | ELTX Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Elicio Therapeutics Lands $10M Funding to Advance Revolutionary Cancer Vaccine Through Critical Trial Phase - Stock Titan

Jun 04, 2025
pulisher
May 29, 2025

When the Price of (ELTX) Talks, People Listen - news.stocktradersdaily.com

May 29, 2025
pulisher
May 20, 2025

Elicio Therapeutics announces board election results By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

Elicio Therapeutics Elects New Directors at Annual Meeting - TipRanks

May 20, 2025
pulisher
May 20, 2025

Elicio Therapeutics announces board election results - Investing.com

May 20, 2025
pulisher
May 14, 2025

Elicio Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Elicio's (ELTX) ELI-002 Interim Analysis Anticipated in Phase 2 Trial | ELTX Stock News - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Elicio Therapeutics: Q1 Earnings Snapshot - CTPost

May 13, 2025
pulisher
May 13, 2025

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire

May 13, 2025
pulisher
May 08, 2025

Learn to Evaluate (ELTX) using the Charts - news.stocktradersdaily.com

May 08, 2025
pulisher
May 01, 2025

Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher - Yahoo Finance

May 01, 2025
pulisher
Apr 23, 2025

Long Term Trading Analysis for (ELTX) - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 16, 2025

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires - GlobeNewswire

Apr 16, 2025
pulisher
Apr 16, 2025

Key Executive Appointment: Elicio Therapeutics Names New Chief Strategy and Financial Officer - Stock Titan

Apr 16, 2025
pulisher
Apr 15, 2025

Elicio Therapeutics grants inducement award to new chief strategy and financial officer - MSN

Apr 15, 2025
pulisher
Apr 06, 2025

(ELTX) Investment Report - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Apr 04, 2025

Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know - MSN

Apr 04, 2025
pulisher
Apr 04, 2025

Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Apr 04, 2025
pulisher
Apr 04, 2025

Earnings Preview: What To Expect From Johnson & Johnson's Report - Barchart.com

Apr 04, 2025
pulisher
Apr 01, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Elicio Therapeutics Advances Cancer Immunotherapy Pipeline - TipRanks

Apr 01, 2025
pulisher
Mar 31, 2025

Elicio signals delay in mid-stage cancer vaccine study; shares slump - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Elicio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Elicio Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Elicio's Latest Financial Results Reveal Key Clinical Milestones and 28.9-Month Survival Data - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

(ELTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 26, 2025

ELICIO THERAPEUTICS Earnings Preview: Recent $ELTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 26, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics Names Preetam Shah CFO -March 24, 2025 at 08:17 am EDT - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch

Mar 24, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics Appoints New Chief Strategy and Financial Officer - TipRanks

Mar 24, 2025
pulisher
Mar 24, 2025

Elicio Therapeutics appoints new CSFO amid clinical trials - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Strategic Move: Elicio Strengthens Leadership Team Ahead of Crucial Phase 2 Trial Results - Stock Titan

Mar 24, 2025
pulisher
Mar 22, 2025

Elicio Therapeutics, Inc. (NASDAQ:ELTX) surges 13%; individual investors who own 49% shares profited along with insiders - simplywall.st

Mar 22, 2025

Elicio Therapeutics Inc Stock (ELTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.16
price down icon 1.86%
$34.86
price down icon 0.14%
$20.56
price up icon 1.98%
$102.68
price up icon 3.24%
$106.53
price up icon 2.04%
biotechnology ONC
$247.08
price down icon 2.25%
Cap:     |  Volume (24h):